Dasatinib 化学構造
分子量: 488.01

高品質保証

文献中の引用(62)

カスタマーフィードバック(10)

MSDS

製品説明

  • Compare Src Inhibitors
    Src製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Dasatinibは一種の新たで、有効な多ターゲット阻害剤で、無細胞試験でAbl、Srcとc-Kitに作用する時のIC50値が1 nM以下、0.8 nMと79 nMにそれぞれ分かれることです。
ターゲット Abl Src c-Kit (WT)/c-Kit (D816V)
IC50

0.6 nM

0.8 nM [1]

79 nM/37 nM [2]
In vitro試験 Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
M07ep210 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTUPXg4OiCq NEi2dZVFVVOR NYL2N3BUUUN3ME2wMlAxODB5IN88US=> MU[xO|k2PjB6MB?=
K562 NITScIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DBN|czKGh? MYXEUXNQ NHvDenpKSzVyPUCuNFAyKM7:TR?= MnPaNVc6PTZyOEC=
M07e MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHFO|IhcA>? MlLRSG1UVw>? MnPqTWM2OD1yLkCwNVIh|ryP MmezNVc6PTZyOEC=
ALL3 MmK2R5l1d3SxeHnjJGF{e2G7 M4\pZlAvOc7:TR?= Mnj4O|IhcA>? M4C1XWROW09? NHrtUYdKSzVyPUCuNFAxPCEQvF2= NWXuXJV5OTl6OEm1OFA>
CML Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCyNEBucW5? MmrDSG1UVw>? M1LONmlEPTB;MD6wNFEh|ryP NXnvSFlYOTl{MUmwNVY>
BA/F3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXS3NkBp M1fsR2ROW09? Mk\oTWM2OD14LkW4PUDPxE1? M{T6UlI{ODh6NkS0
BA/F3 M3;z[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fGSFczKGh? NGXzOFhFVVOR NGTMNXVKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJG0{PTGWIH31eIFvfCC5aYToJGlEPTBib3[gNE4xODB6M988US=> M{PocFI{ODh6NkS0
BA/F3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n0[|czKGh? NXXYZoRoTE2VTx?= NYnZbopQUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?= M4KyOlI{ODh6NkS0
BA/F3 NHvCWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\IO|IhcA>? NVfIeZpMTE2VTx?= NXP4PXAyUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszN M4\tfVI{ODh6NkS0
BA/F3 NV:0XJRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSzO|IhcA>? M{XzPWROW09? M3zQRWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6|ryP MW[yN|MxOTdyMx?=
BA/F3 M1Xtfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS4flk4OiCq NHfzN3FFVVOR NH\Kbm5KdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA{Os7:TR?= NF3kc5MzOzNyMUewNy=>
BA/F3 M3zZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:3NkBp MVTEUXNQ NFLERYpKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA2Oc7:TR?= MmG1NlM{ODF5MEO=
BA/F3 M2i5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXu3NkBp M4n0bGROW09? NWTWSlc1UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= MlHQNlM{ODF5MEO=
BA/F3 NI\yWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXXO|IhcA>? NXj6eodKTE2VTx?= NUX2WWhUUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUO1PXYhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOTQQvF2= NH31PI0zOzNyMUewNy=>
BA/F3 MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7qO|IhcA>? M13IZmROW09? NFH4clRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLDVk1CSkxiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxPe69VQ>? Mlv4NlM{ODF5MEO=
BA/F3 M4fEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[2dWxjPzJiaB?= MWnEUXNQ Ml3vTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1? MnTDNlM{ODF5MEO=
BA/F3 NHK5fodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MniyO|IhcA>? MVPEUXNQ MmLvTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB|LkdOwG0> NEjNemMzOzNyMUewNy=>
BA/F3 MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7MPVA4OiCq NIDDW5RFVVOR MmXITY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP NETZZpozOzNyMUewNy=>
T cell NUHIb5NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXW3NkBp M3fXemROW09? M1XlN2lvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO NIrwV4wyPzF3NEWxNi=>
WiDr MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWO3NkBp M2frSGROW09? NE\lR2lKSzVyPUCuNFUzKM7:TR?= M363b|E2PjF3NUGy
PC3 NYDqd4ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;scJZOPzJiaB?= MVXEUXNQ NWTvS4tKUUN3ME2wMlAxQTRizszN M3HNblE2PjF3NUGy
MDA-MB-231 M3zFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXHdJo4OiCq MXnEUXNQ NF\uU29KSzVyPUCuNFEzKM7:TR?= MnP1NVU3OTV3MUK=
Hs578T MVPDfZRwfG:6aXOgRZN{[Xl? NIm3bFI4OiCq MULEUXNQ NEXTfXlIUTVyPUCuNFMh|ryP NVLoeYFROjRyMUWzNlc>
HMEC M3LLUmN6fG:2b4jpZ{BCe3OjeR?= NXLnWY1tPzJiaB?= NFfPVYZFVVOR MXzHTVUxRTFwODFOwG0> NXnnNWgyOjRyMUWzNlc>
DU145 NYTLRnJ2S3m2b4TvfIlkKEG|c3H5 NI\nNpc4OiCq M4nyfWROW09? M36zXWdKPTB;MD6xOkDPxE1? NES0[2UzPDBzNUOyOy=>
U251 MkH6R5l1d3SxeHnjJGF{e2G7 NHrRUZM4OiCq MkHQSG1UVw>? NUTublhkT0l3ME2yMlgyKM7:TR?= NW\4[G9vOjRyMUWzNlc>
NCI60 M3K0NGN6fG:2b4jpZ{BCe3OjeR?= MVK3NkBp NWrYNY5wTE2VTx?= NW\QWJBNT0l3ME21Mlch|ryP NWf6bIlXOjRyMUWzNlc>
MALME-3M MYDDfZRwfG:6aXOgRZN{[Xl? M4q4[VczKGh? NXLEO3JyTE2VTx?= M3zkSWdKPTB;Nj62NUDPxE1? M1niSFI1ODF3M{K3
KM12 M{W1T2N6fG:2b4jpZ{BCe3OjeR?= MUm3NkBp MoTQSG1UVw>? MYPHTVUxRTdwNESg{txO NIm4eoczPDBzNUOyOy=>
SW620 NHGzSWREgXSxdH;4bYMhSXO|YYm= NVzKPFNQPzJiaB?= M2H5ZmROW09? M1rZe2dKPTB;OD60N{DPxE1? MlWzNlQxOTV|Mke=
RXF 393NL NUKxSnBRS3m2b4TvfIlkKEG|c3H5 MUO0JIRigXN? MYHEUXNQ M124b2lEPTB;MD6wNlE4KM7:TR?= NWTjUWUxOjN{NUOwO|Q>
LXFA 983L MoPJR5l1d3SxeHnjJGF{e2G7 MUC0JIRigXN? MmTjSG1UVw>? MWPJR|UxRTBwMEW2OUDPxE1? NH\MNZYzOzJ3M{C3OC=>
PRXF DU145 NGHaeIZEgXSxdH;4bYMhSXO|YYm= M4Dj[VQh\GG7cx?= M3HKV2ROW09? Ml7tTWM2OD1yLkC2NlMh|ryP NXXid5VtOjN{NUOwO|Q>
PAXF 1657L NHzIbWhEgXSxdH;4bYMhSXO|YYm= NUDm[nNnPCCmYYnz MVHEUXNQ MUHJR|UxRTBwMUKxJO69VQ>? MVKyN|I2OzB5NB?=
CXF 1103L MW\DfZRwfG:6aXOgRZN{[Xl? MYG0JIRigXN? NXPQ[41wTE2VTx?= M2nXd2lEPTB;ND6zOkDPxE1? MmHHNlMzPTNyN{S=
GXF251L M37vWWN6fG:2b4jpZ{BCe3OjeR?= M2\ndlQh\GG7cx?= Mlr4SG1UVw>? NUD6NmdiUUN3ME2yMlI2KM7:TR?= MYSyN|I2OzB5NB?=
NCI-H23 MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUK3NkBp MnjESG1UVw>? Mom1TWM2OD1{LkK3JO69VQ>? NHrvRZczOzV{MUCyNC=>
HCT116 NYjubXR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWe3NkBp MmnMSG1UVw>? NVLLd5hHUUN3ME2yMlMh|ryP M1zWdVI{PTJzMEKw
MCF7 MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK1O4I4OiCq MoiySG1UVw>? MkXqTWM2OD1{LkW3JO69VQ>? NHO3[24zOzV{MUCyNC=>
NCI-H460 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\0UJA4OiCq NGHETJNFVVOR NXe4fYJiUUN3ME24Mlk6KM7:TR?= NWXZc3NMOjN3MkGwNlA>
DLD1 NF;YUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjk[XdXPzJiaB?= MnP3SG1UVw>? NVvyZmpxUUN3ME20MlYh|ryP NXS5TYp5OjN3Nke5OlA>
NCI-H661 M3;YTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGixWmU4OiCq NH\UTYhFVVOR M3TSZ2lEPTB;Nz64JO69VQ>? M3PCR|I{PTZ5OU[w
A549 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjUO|IhcA>? NHnrZpJFVVOR M1PnZ2lEPTB;OD6yJO69VQ>? NYXyeI1COjN3Nke5OlA>
U937 NGqxWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3WyPVczKGh? MlPlSG1UVw>? NELTXXlKSzVyPUGyMlIh|ryP MUWyN|U3Pzl4MB?=
HEK293 NG\TWWJHfW6ldHnvckBCe3OjeR?= NGPR[mUyOMLizszN MnuxSG1UVw>? NHnkcJZKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm|LYTh[4dm\CCPeYSxJItqdmG|ZTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IIfpeIghUUN3MDDv[kAxNjB4M988US=> MWiyNlc4ODZzMB?=
HUVEC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[x[|AvOTYEoN88US=> MUG3NkBp NGHt[pdFVVOR MWDJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2= NWDSfJVpOjJ6NUO5PVM>
HUVEC M1fYV2Z2dmO2aX;uJGF{e2G7 M2rOPVE2yqEQvF2= Mnn2O|IhcA>? NYfzfmZ6TE2VTx?= NYfafpg4UW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1? MnG1NlI5PTN7OUO=
Plasmodium falciparum MVrGeY5kfGmxbjDBd5NigQ>? NUjMSnViOTEEoN88US=> MkTUNVUhdWmw M4rCUmROW09? MWHJcohq[mm2czDQcIF{dW:maYXtJIZidGOrcHHyeY0heHKxbHnm[ZJifGmxbjDifUBqdmirYnn0bY5oKHSqZTDGeY5kfGmxbjDv[kBR\kOGUFuxJJBzd3SnaX6ge4l1cCCLQ{WwJI9nKDFwMUhOwG0> Mn;INlQ2PTB|M{C=
PC3 NEL3NIZHfW6ldHnvckBCe3OjeR?= M3TpNFAvOSEQvF2= NGr3Zm82KGh? MoPGSG1UVw>? MW\Jcohq[mm2czDoeY1idiCSQ{OgZ4VtdCCjZHjld4lwdiCjdDCxNFAhdk1? MniyNVk1PjJ7N{W=
DU145 MV\GeY5kfGmxbjDBd5NigQ>? MnvxNE4yKM7:TR?= MVq1JIg> MV3EUXNQ NHL1dI1KdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW|aX;uJIF1KDFyMDDuUS=> MnnXNVk1PjJ7N{W=
PC3 M2rFV2tqdmG|ZTDBd5NigQ>? M2XPOVAvOSEQvF2= NIrFNpE2KGh? NHXhU3VFVVOR NXTJd3RZUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> M{PZW|E6PDZ{OUe1
DU145 MXXLbY5ie2ViQYPzZZk> NWe4e4w2OC5zIN88US=> M2\HUVUhcA>? MnXISG1UVw>? M{HFXGlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> Ml\4NVk1PjJ7N{W=
PC3 MkHkT4lv[XOnIFHzd4F6 M1HFXlAvOSEQvF2= MYq1JIg> M3jKZ2ROW09? MWHJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> NGnITYwyQTR4Mkm3OS=>
DU145 MYrLbY5ie2ViQYPzZZk> NHrH[5oxNjFizszN NU\URZM4PSCq M{TwSWROW09? NVzEOGtkUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2= NXHReZJZOTl2NkK5O|U>
Huh7 NHvNXHVCdnSrdnnyZYwhSXO|YYm= MUOyMlUh|ryP NGjIVlE1KGSjeYO= Mn3NSG1UVw>? M3\ub2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= NWXvR3NKOTd|NkC2O|Y>
C6/36 MYjBcpRqfmm{YXygRZN{[Xl? NGWwe40zNjVizszN NEnkPVU1KGSjeYO= MW\EUXNQ MlnFTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBie2mjbjD0bYdmeiCvb4PxeYl1dyCFNj:zOkBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VQ>? M4\kd|E4OzZyNke2
U937 NYj6bXdFTnWwY4Tpc44hSXO|YYm= NUDtZnJtOSEQvF2= MUmxJIg> NVrPOZRWTE2VTx?= NX\TTVVSWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= NFrqXHcyPzZ6NEC5PS=>
U937 NIPUZnRHfW6ldHnvckBCe3OjeR?= MWixJO69VQ>? MXexJIg> NF\xeFlFVVOR MW\S[YR2[2W|IFzQV{1qdmS3Y3XkJHRPTmGucHjhJJJmdGWjc3WgbY4hcHWvYX6gWVk{PyClZXzsdy=> NV20SY9xOTd4OESwPVk>
murine mast cell M4S3Z2Z2dmO2aX;uJGF{e2G7 NEfyWlIyKM7:TR?= MXGyOEBp M4LIVmROW09? NIPDbopKdmirYnn0d{BidnSrZ3XuMYlv\HWlZXSgTWw3KHOnY4LleIlwdiCrbjDJ[2UheHKrbXXkJI1wfXOnIH3hd5Qh[2WubIOgZZQhOSC3TR?= NWHXellpOTd4OESwPVk>
BV-173 MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\iOmlKSzVyPUCuNFAxODByMUC5JO69VQ>? NU\1[m1SW0GQR1XS
K-562 M4LPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PINGlEPTB;MD6wNFAxODB{Nk[g{txO MUXTRW5ITVJ?
BL-70 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMECwNFAxQDJ{IN88US=> MnrFV2FPT0WU
EM-2 M131eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rIbmlEPTB;MD6wNFAxODFyODFOwG0> NGfTWIVUSU6JRWK=
LAMA-84 MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMECwNFA{OjFizszN MXLTRW5ITVJ?
MEG-01 MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[wc2t6UUN3ME2wMlAxODByOUig{txO NYrrd3RiW0GQR1XS
EoL-1-cell MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD6bG9mUUN3ME2wMlAxODBzM{Gg{txO MX3TRW5ITVJ?
CTV-1 NEDN[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LpbmlEPTB;MD6wNFAxPDB2IN88US=> M{HM[XNCVkeHUh?=
TE-15 NFjzNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XFRmlEPTB;MD6wNFU5QSEQvF2= M{nocHNCVkeHUh?=
NOS-1 NFHVPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPiTWM2OD1yLkCwOlE{KM7:TR?= NILNTnRUSU6JRWK=
D-336MG NEi1e|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMEC2N{DPxE1? NG\yWG1USU6JRWK=
LB1047-RCC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEC5PFkh|ryP NFKyNmJUSU6JRWK=
LB996-RCC MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMEC5PVEh|ryP NHnrNYpUSU6JRWK=
SW982 NU\6ToJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ewVWlEPTB;MD6wNVEyPSEQvF2= NU[2Tlk3W0GQR1XS
TK10 NWLjSmJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfvTWM2OD1yLkCxNVc1KM7:TR?= MYXTRW5ITVJ?
A704 NWPCO4d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnUVpNKSzVyPUCuNFE1QTFizszN M1;4Z3NCVkeHUh?=
TE-8 NUDBboRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\ydFdiUUN3ME2wMlAyPTd4IN88US=> M2P4fnNCVkeHUh?=
DOHH-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1joZmlEPTB;MD6wNVcyQSEQvF2= MXvTRW5ITVJ?
HOP-62 NImxco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\WV2lEPTB;MD6wNVg{PCEQvF2= M2fT[XNCVkeHUh?=
TE-12 M{HqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPZV|lZUUN3ME2wMlAyQDZzIN88US=> NV3BVYQxW0GQR1XS
KGN M1zmT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEG5OFIh|ryP M4LFXXNCVkeHUh?=
NCI-H1648 NH;sWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\PTWM2OD1yLkCyNFEyKM7:TR?= MorsV2FPT0WU
OS-RC-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMEKwN{DPxE1? MlrWV2FPT0WU
GB-1 NE\2V4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\mb2lEPTB;MD6wNlE2PyEQvF2= MVLTRW5ITVJ?
RXF393 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMEKzOVch|ryP NGLm[49USU6JRWK=
LC-2-ad MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1KxOWlEPTB;MD6wNlU5PiEQvF2= M2jkZ3NCVkeHUh?=
KS-1 Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfXTZJKSzVyPUCuNFI4OyEQvF2= MWfTRW5ITVJ?
ETK-1 M2G1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjHW2tKSzVyPUCuNFI5OzJizszN MoXwV2FPT0WU
SW954 NFnFWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljBTWM2OD1yLkCyPVI4KM7:TR?= NVnDPFlHW0GQR1XS
Becker NUPtSZdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rjbGlEPTB;MD6wN|AxOyEQvF2= NGLaN|BUSU6JRWK=
MZ1-PC NXvoRm1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHSTWM2OD1yLkCzNVE6KM7:TR?= NEHCfVZUSU6JRWK=
ES6 MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTOW3pQUUN3ME2wMlA{OTl|IN88US=> M1G1fnNCVkeHUh?=
KURAMOCHI MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HrXWlEPTB;MD6wN|Q5PyEQvF2= NEjFTGVUSU6JRWK=
CGTH-W-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nseWlEPTB;MD6wN|U1QCEQvF2= M2TTcXNCVkeHUh?=
VA-ES-BJ NHjNSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n6VWlEPTB;MD6wN|kxOiEQvF2= M3fVOnNCVkeHUh?=
LXF-289 NFnMdJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXvTWM2OD1yLkCzPVU3KM7:TR?= MoryV2FPT0WU
MPP-89 NW\FcGI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMESwOFkh|ryP Mn;RV2FPT0WU
SW872 NXXE[lN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMESxOlEh|ryP M3ziVXNCVkeHUh?=
SNB75 M37mVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfqepFKSzVyPUCuNFQ1OzVizszN MmmwV2FPT0WU
PSN1 M{jhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvGOnNnUUN3ME2wMlA1PDd2IN88US=> M1PkfXNCVkeHUh?=
LB831-BLC M3PRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMES2NFkh|ryP NVPaRZdXW0GQR1XS
MFH-ino MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2SwS2lEPTB;MD6wOFczPCEQvF2= MnPmV2FPT0WU
TGBC24TKB NVjVfpdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGxTlFKSzVyPUCuNFQ4PjFizszN M{LQRnNCVkeHUh?=
A388 NGDGPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ntXmlEPTB;MD6wOVA6PSEQvF2= M2jVe3NCVkeHUh?=
BB30-HNC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u1bGlEPTB;MD6wOVQ{PyEQvF2= MYDTRW5ITVJ?
GI-ME-N NXzSSHBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDNTWM2OD1yLkC2NVE5KM7:TR?= MVvTRW5ITVJ?
TGBC1TKB MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXLTWM2OD1yLkC2NVY1KM7:TR?= M{LTRnNCVkeHUh?=
TE-10 M4jHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwME[zOVch|ryP M3TyVnNCVkeHUh?=
A498 NF\wbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDFTWM2OD1yLkC3Nlg1KM7:TR?= MVLTRW5ITVJ?
TE-11 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLlTWM2OD1yLkC3PFU5KM7:TR?= NHTsc|NUSU6JRWK=
BB65-RCC NFTaelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMEiyNlch|ryP MV;TRW5ITVJ?
C2BBe1 M3jlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDqU|dVUUN3ME2wMlA5OzB6IN88US=> MWXTRW5ITVJ?
NCI-H747 NU\Ib5dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYGycotLUUN3ME2wMlA5OzZ{IN88US=> Mm\xV2FPT0WU
IST-MES1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDvPJgzUUN3ME2wMlA5PTV{IN88US=> MoTpV2FPT0WU
KALS-1 MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHGXZFKSzVyPUCuNFk1QSEQvF2= NFzpe4ZUSU6JRWK=
GCIY NEnFR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12wbmlEPTB;MD6wPVY2PiEQvF2= NEntXoFUSU6JRWK=
RL95-2 M3:4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMUCzPEDPxE1? NY\1Wm5ZW0GQR1XS
TE-1 MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfydoVKSzVyPUCuNVA2PCEQvF2= NHXQSJBUSU6JRWK=
NCI-H1355 Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\abodKSzVyPUCuNVExOjhizszN MmfsV2FPT0WU
SW962 NYfINmJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPERZhbUUN3ME2wMlEyOjl{IN88US=> MWDTRW5ITVJ?
KLE MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG2clhKUUN3ME2wMlEyOzF5IN88US=> NXjBSoI2W0GQR1XS
MC116 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC2bWpvUUN3ME2wMlEyPDFizszN M3y4dnNCVkeHUh?=
NMC-G1 NWjjcmlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DVU2lEPTB;MD6xNVYxPiEQvF2= NEC0Vo9USU6JRWK=
KU812 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ThN2lEPTB;MD6xNVg5OyEQvF2= M{DFdHNCVkeHUh?=
COLO-829 NYS2eohrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf1OVV1UUN3ME2wMlEzOjF|IN88US=> M1TwNXNCVkeHUh?=
NTERA-S-cl-D1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMUKyPFMh|ryP Ml\xV2FPT0WU
IST-MEL1 NXr6[2VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X1UWlEPTB;MD6xN|Q2KM7:TR?= NFW5Z4RUSU6JRWK=
MLMA NVXGPVJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjHVFdKSzVyPUCuNVQxOzJizszN M17rcHNCVkeHUh?=
LS-123 M3;UT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Cxd2lEPTB;MD6xOFA3PCEQvF2= MofOV2FPT0WU
LB2518-MEL NX;DXI5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHOUmdKSzVyPUCuNVQyPjJizszN M{nMbHNCVkeHUh?=
NB69 NFGzdnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrmN2hGUUN3ME2wMlE1PDN4IN88US=> Mnm2V2FPT0WU
8-MG-BA MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ftbWlEPTB;MD6xOVQ2QCEQvF2= NU\1PHpNW0GQR1XS
K5 NGfCemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTnTWM2OD1yLkG2OFg6KM7:TR?= MUDTRW5ITVJ?
KINGS-1 M1rSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLlcJhEUUN3ME2wMlE3PjZ4IN88US=> MnzyV2FPT0WU
SF268 M{DSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3mzXmlEPTB;MD6xO|QxPCEQvF2= M3PPTnNCVkeHUh?=
PF-382 NWPXdlZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\wV2l2UUN3ME2wMlE4Pjd6IN88US=> NF\rcGNUSU6JRWK=
SH-4 NYDmR41JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMUi0NVMh|ryP M33PUHNCVkeHUh?=
NALM-6 M3LI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rTbWlEPTB;MD6xPVI6PSEQvF2= M165enNCVkeHUh?=
CP66-MEL MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMUm1N|Eh|ryP MUDTRW5ITVJ?
697 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMUm5PFch|ryP M3zadXNCVkeHUh?=
CP67-MEL MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXhOoNKSzVyPUCuNlA1QDhizszN NFLMS|ZUSU6JRWK=
DSH1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnXVmtKSzVyPUCuNlQxODFizszN NEXnOHFUSU6JRWK=
HCE-4 NEHGdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPBTWM2OD1yLkK2OFM6KM7:TR?= NITXVZZUSU6JRWK=
MZ2-MEL MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTyTWM2OD1yLkK4OVM4KM7:TR?= MXLTRW5ITVJ?
BL-41 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O2cWlEPTB;MD6yPVEzOyEQvF2= NHmzN5pUSU6JRWK=
HUTU-80 M2rPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;zWZJyUUN3ME2wMlMyPDJizszN M2ntb3NCVkeHUh?=
LOXIMVI MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;TbphKSzVyPUCuN|E2ODNizszN NGX0[lJUSU6JRWK=
no-10 MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwM{G5N|Eh|ryP NXTN[4FqW0GQR1XS
KARPAS-422 NW[zZ4NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwM{O5PVch|ryP NYDOZ2FNW0GQR1XS
SW684 M2XjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwM{S5PEDPxE1? Mn35V2FPT0WU
SF126 NXO4Oot7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zvXGlEPTB;MD6zOVQyKM7:TR?= MY\TRW5ITVJ?
D-263MG MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r5emlEPTB;MD6zOlIzPCEQvF2= NY\OZVFNW0GQR1XS
OVCAR-4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF73WHJKSzVyPUCuN|c1OzNizszN M{\LZXNCVkeHUh?=
BB49-HNC Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\RZmlKSzVyPUCuN|g2QTlizszN M37tO3NCVkeHUh?=
ONS-76 NW\Fd|hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwNEK5OVEh|ryP NY\pTWhSW0GQR1XS
MZ7-mel MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvBTWM2OD1yLkS3PVEyKM7:TR?= MV\TRW5ITVJ?
RCC10RGB NVXUW4RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLITWM2OD1yLkS5NVEh|ryP Ml\wV2FPT0WU
BOKU NYS0W5JIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS4c3hPUUN3ME2wMlQ6OTN|IN88US=> MX;TRW5ITVJ?
no-11 NUCz[o9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;FTWM2OD1yLkWwNlI5KM7:TR?= NHnWVo5USU6JRWK=
IST-SL2 NWm3[mtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LlRWlEPTB;MD61NFMxOiEQvF2= MVjTRW5ITVJ?
RKO MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13ncWlEPTB;MD61Nlk3PiEQvF2= MWXTRW5ITVJ?
HT-144 M3mxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLITWM2OD1yLkWzOlA6KM7:TR?= MWXTRW5ITVJ?
NCI-H446 NFLyOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwNkK3OkDPxE1? MlHwV2FPT0WU
QIMR-WIL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n3bGlEPTB;MD63NFYzQSEQvF2= MmH5V2FPT0WU
MHH-PREB-1 NXWxemFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fmSGlEPTB;MD63OFQ3QSEQvF2= NIW1[IhUSU6JRWK=
EW-16 M1KxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13NUWlEPTB;MD63OlE4QCEQvF2= NI\BO2pUSU6JRWK=
EW-24 NXnHbZd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwN{ixOlUh|ryP NHvteZlUSU6JRWK=
LB373-MEL-D MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm5dWdKSzVyPUCuPFI2ODhizszN MXrTRW5ITVJ?
TE-9 M3jXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwOEe1N|Ih|ryP NFWxOlBUSU6JRWK=
A3-KAW NUPLRnQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfVdmlKSzVyPUCuPVg1PTJizszN M2LSPXNCVkeHUh?=
A101D M1PP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTFwMEOwOFMh|ryP NH3VZm5USU6JRWK=
OCUB-M MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDtc3FtUUN3ME2xMlA1PDF{IN88US=> MWDTRW5ITVJ?
ES4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLRTWM2OD1zLkC1NVQ2KM7:TR?= NXzCWpBVW0GQR1XS
TE-6 NHLTN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwMkGyNlYh|ryP NFT3SGlUSU6JRWK=
D-502MG NEnvbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnsbZhIUUN3ME2xMlI{Ozd4IN88US=> M1HvWnNCVkeHUh?=
KNS-42 M{jNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nmVWlEPTB;MT6yOFQyOiEQvF2= MY\TRW5ITVJ?
SNU-C2B Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[1b4JKSzVyPUGuN|A2QDlizszN MV3TRW5ITVJ?
NCI-H1838 MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFwM{C3N|Mh|ryP M{\aeHNCVkeHUh?=
NKM-1 Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfwdnhKSzVyPUGuN|A5PTlizszN NULzWVhpW0GQR1XS
GI-1 M3;2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;hOGlEPTB;MT6zOlIzKM7:TR?= NX2wT|hqW0GQR1XS
NB5 MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUixU2hzUUN3ME2xMlM6QDJ5IN88US=> MVrTRW5ITVJ?
CAS-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X3T2lEPTB;MT60NFk6OiEQvF2= MUnTRW5ITVJ?
HCE-T M1q5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXPbppDUUN3ME2xMlU3PzF2IN88US=> MkPQV2FPT0WU
SBC-1 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITRXXlKSzVyPUGuOVc6QDRizszN MU\TRW5ITVJ?
JiyoyeP-2003 NYj3VndqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwN{O0OlYh|ryP MYLTRW5ITVJ?
TE-5 NWXLOmt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP3O2FKSzVyPUGuO|kyOzlizszN M2S0NHNCVkeHUh?=
CAN MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;wfmlEPTB;MT64NlI2OiEQvF2= NUG4UmtGW0GQR1XS
SK-UT-1 MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrKPWxLUUN3ME2yMlE3Pjl|IN88US=> MUnTRW5ITVJ?
JVM-2 NH;u[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\YfnlKSzVyPUKuN|YzQDRizszN NYfCR5ljW0GQR1XS
LB771-HNC NEjvc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37mcGlEPTB;Mj61O|U2OSEQvF2= NVjhWGZQW0GQR1XS
NCCIT NH\WWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJwOE[2NVYh|ryP NFrO[oFUSU6JRWK=
NCI-H2126 NYrDe|BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki4TWM2OD1{Lki3OVUzKM7:TR?= NGjZRZBUSU6JRWK=
Calu-6 NVfxNY5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLLRlI2UUN3ME2zMlA2PzRzIN88US=> NYD2UWxJW0GQR1XS
SK-LMS-1 NWjFWHV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rqXGlEPTB;Mz6xNVg5PiEQvF2= NFTsWHRUSU6JRWK=
ARH-77 M1LT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q0WWlEPTB;Mz60OlkyPSEQvF2= MkPrV2FPT0WU
NB17 MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTtOI5UUUN3ME2zMlY{QDR5IN88US=> NF;FNG5USU6JRWK=
A253 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnl[IFKSzVyPUOuO|MzPDZizszN MmDLV2FPT0WU
OPM-2 MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rQ[WlEPTB;ND6yO|Y5PSEQvF2= MlmyV2FPT0WU
MV-4-11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojHTWM2OD12LkO2OFU1KM7:TR?= NUTlVHFlW0GQR1XS
SR Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjzTWM2OD12LkS5PVU1KM7:TR?= NFHBWmtUSU6JRWK=
KG-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj1cHhWUUN3ME20MlYxQDR3IN88US=> NY\XOVZ4W0GQR1XS
OCI-AML2 M2e0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi5TWM2OD13Lki2NVU1KM7:TR?= NFXkR4FUSU6JRWK=
D-247MG NVLlS|BtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHRXGpKSzVyPU[uNVI2OTlizszN M1XOTnNCVkeHUh?=
DJM-1 NFuyPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzmVIwzUUN3ME22MlQ5PTV6IN88US=> MYHTRW5ITVJ?
RPMI-6666 NWDkWmV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXH0NlF3UUN3ME23MlI4ODZ5IN88US=> MnzYV2FPT0WU
KARPAS-45 MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDVTWM2OD15LkWxOlcyKM7:TR?= M{myd3NCVkeHUh?=
LP-1 Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof1TWM2OD15LkW0O|gzKM7:TR?= NE\IXJRUSU6JRWK=
RS4-11 NIHne3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV31PYkxUUN3ME23MlY2Pzh5IN88US=> NVTUeFdFW0GQR1XS
DU-4475 M3nmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRThwMkG2OVIh|ryP M3HaW3NCVkeHUh?=
MONO-MAC-6 M2fuWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL4TWM2OD16LkK3NFY3KM7:TR?= NHu4UGhUSU6JRWK=
NCI-SNU-16 M2\pfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jrNWlEPTB;OD61OlEzQCEQvF2= MkfsV2FPT0WU
SJSA-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\RT|NKSzVyPUiuO|I5ODVizszN NU\2R2t1W0GQR1XS
MMAC-SF NYjmc4wxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fweGlEPTB;OD63PVMxPyEQvF2= MkL6V2FPT0WU
SK-NEP-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvEN21qUUN3ME24Mlg6OTV3IN88US=> NYXlToNLW0GQR1XS
J-RT3-T3-5 MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HESGlEPTB;OD65OlUzQSEQvF2= NVHENJdmW0GQR1XS
SKM-1 NVrpbFVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrXTWM2OD17LkCxO|M1KM7:TR?= M2jTW3NCVkeHUh?=
LB2241-RCC NUnINoxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTlwMEKwNVIh|ryP MVfTRW5ITVJ?
SIG-M5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDpd5pYUUN3ME25MlAzPDl|IN88US=> NXPFW3hYW0GQR1XS
EVSA-T NXnVV4FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETLSoxKSzVyPUmuNlc4QTNizszN NGPmOpVUSU6JRWK=
GT3TKB NGm1UFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Lr[2lEPTB;OT6zOVU1PiEQvF2= MVfTRW5ITVJ?
NB6 NFrjUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnsN5BJUUN3ME25MlkzOjV7IN88US=> NYTGNlVXW0GQR1XS
EHEB MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHNcZE2UUN3ME2xNE4xPjV4IN88US=> Ml7aV2FPT0WU
HEL M3;nfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX5dmFUUUN3ME2xNE41Pzd4IN88US=> M{\aN3NCVkeHUh?=
ALL-PO MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnKxTWM2OD1zMD63PVM5KM7:TR?= NXjjZ5ZMW0GQR1XS
TGW NFLMVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTFzLkK4Nlgh|ryP M{fkcnNCVkeHUh?=
BC-3 NV21dlZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7RTWM2OD1zMj6xNVM5KM7:TR?= NXKwcFVMW0GQR1XS
IA-LM M1PMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF{LkS0OFUh|ryP M{jwOXNCVkeHUh?=
UACC-257 NY[zVodpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHSXmFKSzVyPUGyMlkyQThizszN MYLTRW5ITVJ?
KP-N-YS NIDid45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF{LkmyPFMh|ryP NFnWeZFUSU6JRWK=
Raji Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFK4N4FKSzVyPUGzMlc1QTdizszN NGL3NZNUSU6JRWK=
SF539 NHz5TZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH6TWM2OD1zMz64OVU4KM7:TR?= NGjicGhUSU6JRWK=
DMS-153 MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7Gd4FSUUN3ME2xOE4xODJ6IN88US=> NULOU3V[W0GQR1XS
L-540 NYruS3NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF3LkC2O|Ih|ryP NGTNWZBUSU6JRWK=
MN-60 NH3qUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X6TWlEPTB;MUWuNVk4QSEQvF2= MXvTRW5ITVJ?
RPMI-8866 Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLIcI4zUUN3ME2xO{41PDV2IN88US=> MlnvV2FPT0WU
NCI-H510A MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDCTWM2OD1zOT6zPVc{KM7:TR?= NWOzUotiW0GQR1XS
NB13 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPJTWM2OD1zOT60PFc4KM7:TR?= MXzTRW5ITVJ?
HAL-01 MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fyWGlEPTB;MUmuO|U1OyEQvF2= M4DhXXNCVkeHUh?=
NCI-H720 NGPaNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTnTWM2OD1{MD6yO|M{KM7:TR?= MYTTRW5ITVJ?
REH NFT6Sm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXKTWM2OD1{MD62N|U4KM7:TR?= M3\3ZnNCVkeHUh?=
KNS-81-FD M{HkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Ha[WlEPTB;MkOuNVQ3KM7:TR?= MYTTRW5ITVJ?
HC-1 NVe5NIoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfvdJlKSzVyPUK0MlU2PTFizszN NGD2WnhUSU6JRWK=
NCI-H2141 MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnoTWM2OD1{ND63O|U1KM7:TR?= MVzTRW5ITVJ?
MOLT-4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH1d2ZYUUN3ME2yOk43PzV|IN88US=> M2q2OXNCVkeHUh?=
OMC-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrhXolwUUN3ME2yO{4yPDJ{IN88US=> NWHEflh4W0GQR1XS
LC-1F Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rnd2lEPTB;MkeuN|I1PSEQvF2= MVnTRW5ITVJ?
NCI-H1304 Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvETWM2OD1{OD6xOlI5KM7:TR?= NWn5TJlLW0GQR1XS
BC-1 M3jFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rNOWlEPTB;MkiuOlUyKM7:TR?= Ml3RV2FPT0WU
NCI-H64 Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ7Lk[yOVMh|ryP NX[4SHNRW0GQR1XS
MOLT-16 NVrUcnVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf2eZRKSzVyPUK5MlYzQTJizszN MVXTRW5ITVJ?
U-87-MG MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTNyLke2OkDPxE1? MUPTRW5ITVJ?
GAK NFXqS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\PWo1sUUN3ME2zNU4zPjh4IN88US=> NEDMS2VUSU6JRWK=
ES8 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzxTWM2OD1|Mj6xNlUzKM7:TR?= MULTRW5ITVJ?
HCC1599 M1XDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTN{LkOzNlUh|ryP MkGzV2FPT0WU
EB-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrYTWM2OD1|ND6zNVE4KM7:TR?= MnPHV2FPT0WU
HCC1187 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnDTJJEUUN3ME2zOU45ODV{IN88US=> M{nQNHNCVkeHUh?=
SK-PN-DW MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e1ZmlEPTB;M{[uNVk1OyEQvF2= MUnTRW5ITVJ?
JVM-3 NHH1OXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4CxZWlEPTB;M{euNlM{QCEQvF2= NGe0cGRUSU6JRWK=
HCC2157 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWWx[XIzUUN3ME2zO{46QTR4IN88US=> M{POTnNCVkeHUh?=
A4-Fuk M1XGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIiyNXlKSzVyPUO4MlExODlizszN NUPWVWRqW0GQR1XS
COR-L279 Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPESXZkUUN3ME20NE4zQDVzIN88US=> NHPYRZlUSU6JRWK=
DEL M{jYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnWUYZ1UUN3ME20NU46ODh4IN88US=> Ml3qV2FPT0WU
NCI-H1395 MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfXTWM2OD12Mj6wNVY{KM7:TR?= NWizR3k2W0GQR1XS
MHH-NB-11 NVu3bnJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTR|LkC4NVgh|ryP NW\heosyW0GQR1XS
NCI-H2107 NUjvdXpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zkeGlEPTB;NEOuOFg1PiEQvF2= NVHNOldLW0GQR1XS
NEC8 M{TpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3naR2lEPTB;NESuN|M3KM7:TR?= MYPTRW5ITVJ?
COLO-684 MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLKU3BwUUN3ME20Ok4zOjV6IN88US=> NYfiUFFXW0GQR1XS
LS-411N M4LYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTXXZExUUN3ME20PE41PzR6IN88US=> NWTXZodkW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo試験 Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]
臨床試験 Dasatinib has entered in a phase II clinical trial in the treatment of hemangiopericytoma and gastrointestinal stromal tumor.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Kinase autophosphorylation assays Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.

細胞アッセイ:

[1]

細胞株 Ba/F3 cell lines
濃度 ~32 nM
反応時間 72 hours
実験の流れ

Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.

動物実験:

[3]

動物モデル EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
製剤 DMSO
投薬量 30 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Dasatinib SDF
分子量 488.01
化学式

C22H26ClN7O2S

CAS No. 302962-49-8
保管 3年-20℃
2年-80℃in solvent
別名 BMS-354825
溶解度 (25°C) * In vitro DMSO 98 mg/mL (200.81 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide

文献中の引用 (62)

Frequently Asked Questions

  • Question 1
    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

    Answer: Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2
    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

    Answer: Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Src 阻害剤

  • Dasatinib Monohydrate

    Dasatinib Monohydrateは一種の新たで、有効な多ターゲット阻害剤で、Abl、Srcとc-Kitに作用する時のIC50値が1 nM以下、0.8 nMと79 nMにそれぞれ分かれることです。

  • SU6656

    SU6656は一種の選択性的なSrc家族キナーゼ阻害剤で、Src、Yes、LynとFynに作用する時の IC50値が280 nM、20 nM、130 nMと170 nMにそれぞれ分かれることです。

  • PX-478 2HCl

    PX-478 2HClは一種の経口活性をしている、選択性的なHIF-1α阻害剤です。臨床1期。

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878)は一種の選択性的で、経口有効なFAK阻害剤です。臨床2期。

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530)は一種の有効なSrc阻害剤で、無細胞試験でIC50値が2.7 nMです。Saracatinib (AZD0530)はc-Yes、Fyn、Lyn、Blk、FgrとLckにも活性をしていますが、AblとEGFR (L858RとL861Q)に作用する活性が低いです。臨床2/3期。

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Bosutinib (SKI-606)

    Bosutinib (SKI-606)は一種の新たな二重Src/Abl阻害剤で、無細胞試験でIC50値が1.2 nMと1 nMです。

  • KX2-391

    KX2-391は初めの臨床Src阻害剤(ペプチド模倣型)で、Srcのペプチド基質サイトに作用することです。KX2-391は癌細胞系にGI50値が9-60 nMです。臨床2期。

  • PP1

    PP1は一種の有効で、選択性的なSrc阻害剤で、Lck/Fynに作用する時のIC50値が5 nM/6 nMです。

  • PP2

    PP2は一種のSrc家族キナーゼ阻害剤で、無細胞試験でLck/Fynに作用する時のIC50値が4 nM/5 nMです。PP2は、Srcに作用する効果はEGFRに作用する効果より100倍が高くなりますが、ZAP-70、JAK2とPKAに活性を表しません。

最近チェックしたアイテム

Tags: Dasatinibを買う | Dasatinib供給者 | Dasatinibを購入する | Dasatinib費用 | Dasatinib生産者 | オーダーDasatinib | Dasatinib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ